Clinical trial: The effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis - A randomized controlled, cross-over trial

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 9, 2007, Pages 1259-1265

  Janiak, P ^a   Thumshirn, M ^a   Menne, D ^b   Fox, M ^a   Halim, S ^a   Fried, M ^a   Bruhlmann P ^a   Distler, O ^a   Schwizer, W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Menne Biomed   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PLACEBO; RANITIDINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PH MEASUREMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH PH; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; RANITIDINE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 35448971860     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03469.x     Document Type: Article

References (25)

1. Sjögren R. Gastrointestinal motility disorder in scleroderma. Arthritis Rheum 1994 37 : 1265 82.
2. Viani F, Verdu E, Idström J, et al. Effect of omeprazole on regional and temporal variations in intragastric acidity. Digestion 2002 65 : 2 10.
3. Peghini P, Katz P, Bedassy N, et al. Nocturnal acid breakthrough during twice daily (BID) administration of proton pump inhibitor (PPI). Gastroenterology 1997 112 : A255.
4. Peghini P, Katz P, Bracy N, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998 93 : 763 7.
5. Katz PO, Anderson C, Khoudry R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998 12 : 1231 4.
6. Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999 13 : 1467 71.
7. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000 14 : 709 14.
8. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and oesophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1998 93 : 763 7.
9. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998 25 : 1235 40.
10. Peghini P, Katz P, Gilbert J, et al. Ranitidine controls nocturnal gastric breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998 115 : 1335 9.
11. Khoury RM, Katz PO, Hammod R, et al. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999 13 : 675 8.
12. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995 82 : 216 22.
13. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomized controlled trial. Lancet 2001 357 : 1738 42.
14. Ruof J, Bühlmann B, Michel BA, et al. Development and validation of a self-administered systemic sclerosis questionnaire (SYSQ). Rheumatology 1999 38 : 535 42.
15. Fox M, Hebbard G, Janiak P, et al. High-resolution manometry predicts the success of oesophageal bolus transport and identifies clinically important abnormalities not detected by conventional manometry. Neurogastroenterol Motil 2004 16 : 533 42.
16. Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001 49 : 145 51.
17. Johnsson F, Joelsson B. Reproducibility of ambulatory oesophageal pH monitoring. Gut 1988 29 : 886 9.
18. Scarpulla G, Camilleri S, Galante P, Manganaro M, Fox M. The impact of prolonged pH measurements on the diagnosis of gastro-oesophageal reflux disease: four day wireless pH studies. Am J Gastroenterol 2007, in press.
19. Ihaka R, Gentleman R. A language for data analysis and graphics. J Comput Graph Stat 1996 5 : 299 314.
20. Ours T, Fackler W, Richter J, et al. Nocturnal acid breakthrough: clinical significance and correlation with oesophageal acid exposure. Am J Gastroenterol 2003 98 : 517 8.
21. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002 122 : 625 32.
22. Mela G, Savarino V, Vigneri S, et al. Limitations of continuous 24-h intragastric pH monitoring in the diagnosis of duodenogastric reflux. Am J Gastroenterol 1995 90 : 933 7.
23. 2-receptor antagonists. Dig Dis Sci 1999 44 : 1703 9.
24. Xue S, Katz P, Banerjee P, et al. Bedtime H2 blockers improve nocturnal acid gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001 15 : 1351 6.
25. Hendel L, Hage E, Hendel J, et al. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992 6 : 565 77.